Clinical Trials Browser

Phase 1/2 × OTHER × Epirubicin × Clear all

NCT03356860 2024-11-20

B-IMMUNE

Phase 1/2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03277924 2024-08-13

ImmunoSarc

Phase 1/2 Completed

Chondrosarcoma, Extraskeletal Myxoid, Bone Neoplasms, Chondrosarcoma, Hemangioendothelioma, Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT05981014 2023-08-08

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT04836156 2022-04-06

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

Phase 1/2 Recruiting

HER2-negative Early Breast Cancer

NCT02987244 2016-12-08

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

Phase 1/2 Unknown

Lymphoma, T-Cell

NCT00130936 2016-02-15

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

Phase 1/2 Terminated

Gastrointestinal

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms

NCT00057980 2012-06-11

Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00705315 2010-08-19

Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer

Phase 1/2 Completed

Breast Neoplasms